Trial Profile

Phase I Study of BAY 43-9006 (NSC 724772) [sorafenib] in Patients With Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary)
Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions

Most Recent Events

13 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
06 Nov 2010 Status changed from recruiting to active, no longer recruiting, according to the M.D. Anderson Cancer Center record.
06 Nov 2010 Status changed from recruiting to active, no longer recruiting, according to the M.D. Anderson Cancer Center record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com